EA201200975A1 - Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение - Google Patents

Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение

Info

Publication number
EA201200975A1
EA201200975A1 EA201200975A EA201200975A EA201200975A1 EA 201200975 A1 EA201200975 A1 EA 201200975A1 EA 201200975 A EA201200975 A EA 201200975A EA 201200975 A EA201200975 A EA 201200975A EA 201200975 A1 EA201200975 A1 EA 201200975A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activators
pyridinion
amphic
tieno
therapeutic application
Prior art date
Application number
EA201200975A
Other languages
English (en)
Other versions
EA020588B1 (ru
Inventor
Даниель Краво
Софи Халлаку-Бозек
Себастьен Больз
Франк Лёпифр
Лоран Фаверьель
Жан-Дени Дюран
Кристин Шарон
Original Assignee
Поксел
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Поксел filed Critical Поксел
Publication of EA201200975A1 publication Critical patent/EA201200975A1/ru
Publication of EA020588B1 publication Critical patent/EA020588B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к соединениям, которые являются прямыми активаторами АМФК (АМФ-активируемая протеинкиназа), и их применению в лечении нарушений, регулируемых путем активации АМФК. Например, соединения по изобретению являются пригодными для лечения диабетов, метаболического синдрома, ожирения, воспаления, рака и сердечно-сосудистых заболеваний.
EA201200975A 2009-12-29 2010-12-28 ТИЕНО[2,3-b]ПИРИДИНДИОНОВЫЕ АКТИВАТОРЫ АМФК И ИХ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ EA020588B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306344 2009-12-29
PCT/EP2010/070811 WO2011080277A1 (en) 2009-12-29 2010-12-28 Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
EA201200975A1 true EA201200975A1 (ru) 2012-12-28
EA020588B1 EA020588B1 (ru) 2014-12-30

Family

ID=41691577

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200975A EA020588B1 (ru) 2009-12-29 2010-12-28 ТИЕНО[2,3-b]ПИРИДИНДИОНОВЫЕ АКТИВАТОРЫ АМФК И ИХ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Country Status (24)

Country Link
US (1) US9365584B2 (ru)
EP (1) EP2519527B1 (ru)
JP (1) JP5559894B2 (ru)
KR (1) KR101469002B1 (ru)
CN (1) CN102803269B (ru)
AU (1) AU2010338280B2 (ru)
BR (1) BR112012016330B8 (ru)
CA (1) CA2784553C (ru)
CY (1) CY1114952T1 (ru)
DK (1) DK2519527T3 (ru)
EA (1) EA020588B1 (ru)
ES (1) ES2445537T3 (ru)
HR (1) HRP20140035T1 (ru)
IL (1) IL220432A (ru)
ME (1) ME01558B (ru)
MX (1) MX2012007548A (ru)
PL (1) PL2519527T3 (ru)
PT (1) PT2519527E (ru)
RS (1) RS53282B (ru)
SI (1) SI2519527T1 (ru)
SM (1) SMT201400013B (ru)
TW (1) TWI574968B (ru)
WO (1) WO2011080277A1 (ru)
ZA (1) ZA201205604B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012335088B2 (en) * 2011-11-11 2017-08-24 Gilead Apollo, Llc ACC inhibitors and uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2017011917A1 (en) * 2015-07-23 2017-01-26 Thrasos Therapeutics Inc. Methods for treating and preventing polycystic kidney diseases (pkd) using amp-activated protein kinase (ampk) modulators and activators
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
JP2019502660A (ja) 2015-11-25 2019-01-31 ギリアド アポロ， エルエルシー ピラゾールａｃｃ阻害剤およびその使用
JP2019503338A (ja) 2015-11-25 2019-02-07 ギリアド アポロ， エルエルシー ２，４−ジオキソ−１，４−ジヒドロチエノ［２，３−ｄ］ピリミジンの誘導体を含む殺真菌組成物
SI3380479T1 (sl) 2015-11-25 2023-04-28 Gilead Apollo, Llc Triazolni inhibitorji ACC in uporabe le-teh
ES2855348T3 (es) 2015-11-25 2021-09-23 Gilead Apollo Llc Inhibidores de éster ACC y usos de los mismos
CA3172549A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
TWI680122B (zh) 2016-09-07 2019-12-21 國立陽明大學 活化腺苷單磷酸活化蛋白激酶之化合物
KR20190126920A (ko) 2017-03-28 2019-11-12 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
HUE027857T2 (en) * 2008-04-11 2016-11-28 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators

Also Published As

Publication number Publication date
EP2519527B1 (en) 2013-12-18
HRP20140035T1 (hr) 2014-02-14
SI2519527T1 (sl) 2014-06-30
CA2784553A1 (en) 2011-07-07
US9365584B2 (en) 2016-06-14
TWI574968B (zh) 2017-03-21
JP5559894B2 (ja) 2014-07-23
BR112012016330B1 (pt) 2021-03-23
CY1114952T1 (el) 2016-12-14
BR112012016330A2 (pt) 2018-04-03
BR112012016330B8 (pt) 2021-05-25
US20130053401A1 (en) 2013-02-28
ZA201205604B (en) 2013-05-29
JP2013515758A (ja) 2013-05-09
IL220432A (en) 2015-02-26
ME01558B (me) 2014-04-20
KR101469002B1 (ko) 2014-12-04
MX2012007548A (es) 2012-07-23
KR20120120232A (ko) 2012-11-01
RS53282B (en) 2014-08-29
DK2519527T3 (da) 2014-01-27
SMT201400013B (it) 2014-05-07
AU2010338280A1 (en) 2012-07-26
EA020588B1 (ru) 2014-12-30
WO2011080277A1 (en) 2011-07-07
CA2784553C (en) 2014-08-19
CN102803269B (zh) 2016-01-13
CN102803269A (zh) 2012-11-28
PL2519527T3 (pl) 2014-06-30
AU2010338280B2 (en) 2013-08-22
PT2519527E (pt) 2014-02-17
EP2519527A1 (en) 2012-11-07
ES2445537T3 (es) 2014-03-03
TW201144318A (en) 2011-12-16

Similar Documents

Publication Publication Date Title
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
TN2015000283A1 (fr) Functionalized exendin-4 derivatives
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
EA201200402A1 (ru) Новые пиримидиновые и триазиновые антагонисты гепсидина
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
EA200802204A1 (ru) Применение ингибиторов dpp iv
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
CL2008001215A1 (es) Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer.
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
EA201190209A1 (ru) Соединения для лечения метаболических расстройств
EA201190208A1 (ru) Соединения для лечения метаболических расстройств
SV2007002235A (es) Nuevos derivados de pirimidina y su uso ref. bhc041311-sv

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM